Study of Safety and Efficacy of CFZ533 in Type 1 Diabetes Pediatric and Young Adult Subjects
Status:
Recruiting
Trial end date:
2027-06-09
Target enrollment:
Participant gender:
Summary
The study is a Phase 2, multicounty, multicenter, non-confirmatory, investigator- and subject
masked, randomized, placebo-controlled study to evaluate the safety, tolerability,
pharmacokinetics, and efficacy of CFZ533 on preservation of residual pancreatic β-cell
function in new onset T1DM in pediatric and young adult subjects.